DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma
BACKGROUND: Multiple myeloma (MM) is a heterogeneous plasma cell malignancy that remains challenging to cure. Global hypomethylation correlates with an aggressive phenotype of the disease, while hypermethylation is observed at particular regions of myeloma such as B cell-specific enhancers. The recently discovered active epigenetic mark 5-hydroxymethylCytosine (5hmC) may also play a role in tumor biology; however, little is known about its level and distribution in myeloma. In this study, we investigated the global level and the genomic localization of 5hmC in myeloma cells from 40 newly diagnosed patients, including paired relapses, and of control individuals.
RESULTS: Compared to normal plasma cells, we found global 5hmC levels to be lower in myeloma (P < 0.001). Higher levels of 5hmC were found in lower grades of the International Staging System prognostic index (P < 0.05) and tend to associate with a longer overall survival (P < 0.1). From the hydroxymethylome data, we observed that the remaining 5hmC is organized in large domains overlapping with active chromatin marks and chromatin opening. We discovered that 5hmC strongly persists at key oncogenic genes such as CCND1, CCND2 and MMSET and characterized domains that are specifically hydroxymethylated in myeloma subgroups. Novel 5hmC-enriched domains were found at putative enhancers of CCND2 and MYC in newly diagnosed patients.
CONCLUSIONS: 5hmC level is associated with clinical aspects of MM. Mapping 5hmC at a genome-wide level provides insights into the disease biology directly from genomic DNA, which makes it a potent mark to study epigenetics on large patient cohorts.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Clinical epigenetics - 12(2020), 1 vom: 02. Nov., Seite 163 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alberge, Jean-Baptiste [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.10.2021 Date Revised 26.10.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s13148-020-00953-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM317071742 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM317071742 | ||
| 003 | DE-627 | ||
| 005 | 20231225162448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13148-020-00953-y |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1056.xml |
| 035 | |a (DE-627)NLM317071742 | ||
| 035 | |a (NLM)33138842 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alberge, Jean-Baptiste |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.10.2021 | ||
| 500 | |a Date Revised 26.10.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Multiple myeloma (MM) is a heterogeneous plasma cell malignancy that remains challenging to cure. Global hypomethylation correlates with an aggressive phenotype of the disease, while hypermethylation is observed at particular regions of myeloma such as B cell-specific enhancers. The recently discovered active epigenetic mark 5-hydroxymethylCytosine (5hmC) may also play a role in tumor biology; however, little is known about its level and distribution in myeloma. In this study, we investigated the global level and the genomic localization of 5hmC in myeloma cells from 40 newly diagnosed patients, including paired relapses, and of control individuals | ||
| 520 | |a RESULTS: Compared to normal plasma cells, we found global 5hmC levels to be lower in myeloma (P < 0.001). Higher levels of 5hmC were found in lower grades of the International Staging System prognostic index (P < 0.05) and tend to associate with a longer overall survival (P < 0.1). From the hydroxymethylome data, we observed that the remaining 5hmC is organized in large domains overlapping with active chromatin marks and chromatin opening. We discovered that 5hmC strongly persists at key oncogenic genes such as CCND1, CCND2 and MMSET and characterized domains that are specifically hydroxymethylated in myeloma subgroups. Novel 5hmC-enriched domains were found at putative enhancers of CCND2 and MYC in newly diagnosed patients | ||
| 520 | |a CONCLUSIONS: 5hmC level is associated with clinical aspects of MM. Mapping 5hmC at a genome-wide level provides insights into the disease biology directly from genomic DNA, which makes it a potent mark to study epigenetics on large patient cohorts | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a DNA modifications | |
| 650 | 4 | |a Epigenetics | |
| 650 | 4 | |a Hydroxymethylation | |
| 650 | 4 | |a Multiple myeloma | |
| 650 | 7 | |a CCND1 protein, human |2 NLM | |
| 650 | 7 | |a CCND2 protein, human |2 NLM | |
| 650 | 7 | |a Chromatin |2 NLM | |
| 650 | 7 | |a Cyclin D2 |2 NLM | |
| 650 | 7 | |a MYC protein, human |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-myc |2 NLM | |
| 650 | 7 | |a Repressor Proteins |2 NLM | |
| 650 | 7 | |a 5-hydroxymethylcytosine |2 NLM | |
| 650 | 7 | |a 1123-95-1 |2 NLM | |
| 650 | 7 | |a Cyclin D1 |2 NLM | |
| 650 | 7 | |a 136601-57-5 |2 NLM | |
| 650 | 7 | |a 5-Methylcytosine |2 NLM | |
| 650 | 7 | |a 6R795CQT4H |2 NLM | |
| 650 | 7 | |a Histone-Lysine N-Methyltransferase |2 NLM | |
| 650 | 7 | |a EC 2.1.1.43 |2 NLM | |
| 650 | 7 | |a NSD2 protein, human |2 NLM | |
| 650 | 7 | |a EC 2.1.1.43 |2 NLM | |
| 700 | 1 | |a Magrangeas, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Mirko |e verfasserin |4 aut | |
| 700 | 1 | |a Denié, Soline |e verfasserin |4 aut | |
| 700 | 1 | |a Guérin-Charbonnel, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Campion, Loïc |e verfasserin |4 aut | |
| 700 | 1 | |a Attal, Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Avet-Loiseau, Hervé |e verfasserin |4 aut | |
| 700 | 1 | |a Carell, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Moreau, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Minvielle, Stéphane |e verfasserin |4 aut | |
| 700 | 1 | |a Sérandour, Aurélien A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical epigenetics |d 2010 |g 12(2020), 1 vom: 02. Nov., Seite 163 |w (DE-627)NLM205276547 |x 1868-7083 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:1 |g day:02 |g month:11 |g pages:163 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13148-020-00953-y |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 1 |b 02 |c 11 |h 163 | ||